Show/Hide Menu

Existing Partnerships

The Company has a growing number of research and development agreements relating to its proprietary development strategy. The following is a brief description of these agreements (in alphabetical order).

Aptevo Therapeutics

In August 2014, MorphoSys and Aptevo Therapeutics, a spin-off from Emergent BioSolutions, announced a co-development and co-promotion agreement for MOR209/ES414. This compound is a bi-specific anti-PSMA/anti-CD3 antibody targeting prostate cancer that was developed by Aptevo based on its proprietary ADAPTIR™ platform (modular protein technology).

In early March 2015 a phase 1 clinical study with MOR209/ES414 in patients suffering from metastatic castration-resistant prostate cancer (mCRPC) started.


Astellas Pharma

MorphoSys and Astellas Pharma entered into a license agreement for the use of MorphoSys’s HuCAL technology in March 2007. In February 2008, Astellas decided to extend the active collaboration between the two companies for four more years until 2012.

In July 2008, Astellas exercised a pre-existing option to use MorphoSys’s proprietary RapMAT technology for faster antibody optimization as part of the existing technology transfer agreements between the two companies. As a result, MorphoSys receives annual user fees for the RapMAT technology in addition to user fees for the HuCAL platform.


Bayer AG

The active collaboration with Bayer AG was concluded by the end of 2007. Several therapeutic antibody programs are currently in development and could result in future development-dependent milestone payments and royalties on product sales. Bayer AG is currently evaluating two HuCAL-based programs in clinical trials, namely the HuCAL-derived antibody-drug conjugate anetumab ravtansine in the therapeutic area of oncology as well as the HuCAL-antibody BAY1093884 against bleeding disorders (hemophilia).


Boehringer Ingelheim

The active collaboration with Boehringer Ingelheim was concluded in 2010 but therapeutic programs initiated during the course of the active collaboration continue being developed and may result in future milestone payments and royalties on product sales. Boehringer Ingelheim is currently evaluating the HuCAL-based antibody Xentuzumab (BI 836845) against cancer in clinical trials.


Daiichi Sankyo

In March 2006, MorphoSys and Daiichi Sankyo entered into a license agreement and therapeutic antibody collaboration for an initial two-year term with the option of an extension of up to three more years. In March 2008, the collaboration was extended until March 2011.

In October 2009, MorphoSys announced an additional agreement with Daiichi Sankyo in the discovery and development of therapeutic antibodies for hospital-acquired infections. Daiichi Sankyo became MorphoSys’s first collaborator for HuCAL PLATINUM-based drug discovery in infectious diseases. Daiichi Sankyo also agreed to fund the development of certain infectious disease-specific technologies at MorphoSys which will be used to identify the most effective antibody-based drugs.


G7 Therapeutics

In August 2015, MorphoSys and G7 Therapeutics announced that they have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors (GPCRs) and potentially other disease-related transmembrane proteins such as ion channels. Under the terms of the agreement, G7 Therapeutics will generate a set of disease-relevant receptors proposed by MorphoSys. MorphoSys will then apply its proprietary Ylanthia antibody library to discover and develop antibody therapeutics against these receptors. MorphoSys has the right to sublicense to third parties the access to these targets in conjunction with therapeutic antibody candidates.


Galapagos

In November 2008, MorphoSys and Galapagos announced the launch of a long-term codevelopment alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.

The alliance spans all activities from target discovery through to completion of proof of concept clinical trials of novel therapeutic antibodies. Following proof of concept in human clinical trials, programs will be partnered for subsequent development, approval and marketing. Both companies will contribute their core technologies and expertise to the alliance. Galapagos will provide antibody targets implicated in bone and joint disease in addition to its adenoviral target discovery platform to discover further targets for antibody development. MorphoSys will contribute its HuCAL antibody technologies to generate fully human antibodies directed against these targets. Under the terms of the agreement, Galapagos and MorphoSys will share the research and development costs and all future revenues equally.

MOR106 is the first compound derived from this alliance in clinical development against inflammatory diseases.


GeneFrontier / Kaneka

Under the terms of a therapeutic target sourcing collaboration signed in 2007, GeneFrontier may utilize MorphoSys’s HuCAL GOLD antibody library to generate novel HuCAL antibodies against targets provided by leading Japanese research institutes and universities. For this purpose, the HuCAL antibody technology was installed at GeneFrontier’s research laboratories within a research facility in Tokyo. GeneFrontier pays compensation for access to HuCAL GOLD.


GlaxoSmithKline

In June 2013, MorphoSys announced that they have entered into a global agreement with GlaxoSmithKline (GSK) to develop and commercialize MOR103. MOR103 is MorphoSys's proprietary HuCAL-derived antibody against GM-CSF.

Under the terms of the agreement, GSK will assume responsibility for all subsequent development and commercialization of MOR103. As part of the agreement, MorphoSys receives an immediate upfront payment of EUR 22.5 million. On achievement of certain developmental, regulatory, commercial and sales-based milestones, MorphoSys would be eligible to receive additional payments from GSK of up to EUR 423 million, in addition to tiered, double-digit royalties on net sales.

MOR103/GSK3196 is currently in phase 2 clinical development against rheumatoid arthritis as well as hand osteoarthritis.


Heptares

In February 2013, MorphoSys and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody therapeutics targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases. Under the terms of the agreement, Heptares will generate stabilized receptors (StaRs) for a set of GPCR disease targets proposed by MorphoSys. MorphoSys will then apply its Ylanthia antibody library to discover and develop antibody therapeutics against these StaRs. MorphoSys has the right to sublicense to third parties access to these targets in conjunction with therapeutic antibody candidates. Heptares will receive upfront and research funding payments, plus a share of future sublicensing revenues generated by MorphoSys. Heptares also chose Ylanthia to develop and commercialize one therapeutic antibody created by MorphoSys against a GPCR target selected by Heptares. In this case, MorphoSys is eligible to receive license fees, milestones and royalties on any Ylanthia antibody developed by Heptares.


Immatics Biotechnologies

In August 2015, MorphoSys and Immatics Biotechnologies entered a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells. The collaboration agreement provides MorphoSys with access to several proprietary tumor-associated peptides (TUMAPs) discovered using Immatics' XPRESIDENT® platform to develop novel antibody-based therapeutics against these targets in a number of solid and hematological cancers. XPRESIDENT enables access to novel antibody targets associated with proteins that are present inside cancer cells. In return, Immatics will be provided with MorphoSys' Ylanthia antibodies against a number of its TUMAPs, with proprietary development rights. The companies will pay each other milestones based on their respective development progress as well as royalties on marketed products.


Janssen Biotech

The active collaboration with Janssen Biotech (formerly Centocor Ortho Biotech), a wholly owned subsidiary of US pharmaceutical company Johnson & Johnson, was concluded by the end of 2007. Several therapeutic antibody programs are currently in development and could result in future development-dependent milestone payments and royalties on product sales. The most advanced compound within this collaboration is guselkumab (CNTO 1959) against psoriasis. Two additional programs are being evaluated in phase 2 clinical trials.


MD Anderson

In May 2016, MorphoSys and The University of Texas MD Anderson Cancer Center entered a long-term strategic alliance to generate antibody-based therapeutics against cancer. The collaboration agreement provides MorphoSys to work with MD Anderson's Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit, a platform of MD Anderson's with a combination of industry and academic science expertise in the development of monoclonal antibodies. MorphoSys will apply its proprietary Ylanthia technology to generate and optimize fully human antibody candidates against jointly selected targets.


Merck & Co.

In December 2005, MorphoSys signed a five-year license agreement with US pharmaceutical company Merck & Co., Inc. for the use of MorphoSys’s HuCAL GOLD and AutoCAL technologies in research and development of human therapeutic antibodies. The agreement enables Merck to develop up to ten HuCAL-derived therapeutic antibodies in a range of indications. The active collaboration was concluded, as planned, at the end of 2010.

In May 2006, MorphoSys and Schering-Plough signed a license agreement for the use of MorphoSys’s HuCAL GOLD technology in the research and development of human therapeutic antibodies. Schering Plough was acquired by Merck during the course of 2009. The active collaboration was concluded, as planned, in mid 2011.


Merck

In June 2014, MorphoSys and Merck announced an agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints.

Under the terms of the agreement, MorphoSys and Merck will join forces to develop therapies that modulate the immune system's natural ability to fight tumors. MorphoSys will apply its proprietary Ylanthia antibody phage library and technology platform to identify antibodies against the targets of interest. Merck will be fully responsible for execution of development from Phase 1 onwards.


Novartis

MorphoSys and Novartis started working together in 2004 in a collaboration that has so far resulted in multiple active therapeutic antibody programs across various diseases and the first IND filing in September 2007 — just three years after initiation. In December 2007, MorphoSys and Novartis substantially extended their previous relationship and forged one of the most comprehensive strategic alliances in the discovery and development of biopharmaceuticals. Based on a ten-year term, committed annual payments total more than US$ 600 million in technology access, internalization fees and R&D funding, excluding reimbursement of R&D costs related to early-stage development activities. Total payments under the agreement, including committed payments and probability-weighted success-based milestones, contingent upon successful clinical development and market approval of multiple products, could potentially exceed US$ 1 billion, assuming the collaboration successfully runs its maximum term. In addition to these payments, MorphoSys would also be entitled to royalty payments and/or profit sharing on any future product sales. Additionally, MorphoSys also has options to participate in certain development activities in various programs, with part of the early-stage costs being funded by Novartis. Under the codevelopment options, MorphoSys may elect to participate in these projects through cost and profit-sharing with financial participation reflecting its level of investment in the respective programs.

In 2009, Novartis committed to a ten-year term of the strategic alliance. The decision was based on MorphoSys’s successful achievement of certain predefined improvements in its proprietary technologies. The collaboration will run until 2017 and may be extended by Novartis for an additional two years beyond that time under the same financial terms and conditions. Novartis has currently 13 HuCAL antibodies in clinical development.

In November 2012 MorphoSys and Novartis agreed to update the alliance with the latest technology platform Ylanthia. This expansion of the existing strategic alliance marks the commercial launch of Ylanthia and should result in even better therapeutic antibodies which can be made faster than was previously possible.


OncoMed Pharmaceuticals

The active collaboration with US-based biopharmaceutical company OncoMed Pharmaceuticals was concluded in 2010, but therapeutic programs initiated during the course of the active collaboration can continue development and result in future milestone payments and royalties on product sales. OncoMed is currently evaluating a HuCAL-based cancer antibody, namely Tarextumab (OMP-59R5), in phase 2 clinical trials. A second HuCAL-antibody, Vantictumab (OMP-18R5), which targets the Wnt signaling pathway, is currently evaluated in a Phase 1 trial in patients with advanced solid tumors.


Pfizer

The active collaboration with Pfizer based on the HuCAL technology platform was concluded in 2010 but therapeutic programs initiated during the course of the active collaboration can continue development and result in future milestone payments and royalties on product sales. Pfizer currently is evaluating one HuCAL antibody in phase 2 clinical trials, namely Utomilumab (PF-05082566), a cancer antibody.

Additionally, MorphoSys and Pfizer signed a non-exclusive license and technology transfer agreement based on a new technology platform in 2010. The agreement covers the installation, training and use of the technology platform Slonomics for the fabrication of highly-diverse gene and protein libraries at Pfizer’s subsidiary Rinat Neuroscience Corp. in South San Francisco. MorphoSys’s subsidiary Sloning BioTechnology GmbH received an upfront payment and stands to receive annual license fees over the patent lifetime of the Slonomics technology platform.


ProChon Biotech

The active collaboration with ProChon Biotech was concluded but therapeutic programs initiated during the course of the active collaboration can continue development and result in future milestone payments and royalties on product sales. Under the original agreement, MorphoSys applied its innovative HuCAL antibody library to generate human antibodies against a human growth factor receptor associated with various skeletal disorders including achondroplasia, the most common form of human dwarfism, and certain cancers.


Roche

In September 2000, MorphoSys and Roche announced the signing of an agreement under which the companies collaborate on the development of human therapeutic antibodies for a Roche biological target associated with Alzheimer’s disease. In the context of the collaboration, MorphoSys is eligible to receive development-related milestone payments and royalties on any marketed products emerging from the collaboration. Roche is currently evaluating the HuCAL-derived antibody program Gantenerumab in phase 3 clinical trials in Alzheimer’s disease patients.

Expanding on the relationship in Alzheimer’s disease, MorphoSys and Roche announced a new collaboration to develop new therapeutic antibodies in oncology in March 2006.


Temple University

In April 2014, MorphoSys and The Moulder Center for Drug Discovery Research, a unit of Temple University's School of Pharmacy, Philadelphia, Pa., USA, announced a strategic alliance focused on the discovery of new therapeutic antibodies. Under the terms of the agreement, the Moulder Center will receive access to MorphoSys's Ylanthia technology for use in validating new disease-related targets and generating therapeutic antibody candidates. MorphoSys holds an exclusive option to develop any resulting antibodies.

The Ylanthia library will be installed at Temple's Moulder Center for Drug Discovery Research. Its Biotherapeutics Discovery Unit is dedicated to working on drug design and lead optimization in multiple disease areas, including cancer, Alzheimer's disease, cardiovascular, metabolic and viral diseases.


Xencor

In June 2010, MorphoSys AG and US-based biopharmaceutical company Xencor signed a worldwide exclusive license and collaboration agreement. The agreement provided MorphoSys with an exclusive worldwide license to XmAb5574/MOR208 for the treatment of cancer and other indications. As part of the agreement, the companies collaborated on a phase 1 trial in patients with chronic lymphocytic leukemia in the US. Since the successful completion of this clinical trial, MorphoSys is solely responsible for further clinical development . MOR208 is currently being evaluated in a phase 2/3 clinical trial in DLBCL as well as in additional phase 2 trials in DLBCL and CLL.

Xencor has received an upfront payment of US$ 13 million (approx. € 10.5 million), and will be eligible to receive development-, regulatory- and commercialization-related milestone payments and tiered royalties based on product sales.